Trial Profile

Sorafenib to Treat AML Patients With FLT3-ITD Mutation: a Non-interventional Cohort Study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use

Most Recent Events

03 Aug 2022 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified July February 2020 ).
03 Feb 2020 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
03 Feb 2020 Planned primary completion date changed from 1 May 2019 to 1 May 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com